Enterprise Value
752.2M
Cash
315.3M
Avg Qtr Burn
-49.41M
Short % of Float
8.37%
Insider Ownership
8.00%
Institutional Own.
88.77%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HEMGENIX® (etranacogene dezaparvovec-drlb) (AMT-061) Details Hemophilia, Rare diseases, Rare genetic disease | Approved Update | |
Phase 1/2 Data readout |